Critical appraisal of multiple sclerosis guideline in Indonesia
DOI:
https://doi.org/10.30574/gscbps.2018.5.2.0099Keywords:
Multiple sclerosis, Guidelines, Indonesia, Critical appraisalAbstract
Multiple sclerosis (MS) is an autoimmune disease and an incurable. The MS guideline is available in Indonesia. The guideline was developed by Indonesian Neurological Association. The appraisal of these guideline is not yet performed. The aim of this study is to assess the quality of multiple sclerosis guidelines in Indonesia using Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument. The search was obtained to identify MS guideline in Indonesia. The guideline assessed using AGREE II instrument. There are 23 key items organized within 6 domains and each key items were rated on a 7-point scale. After calculating each domain, the result interpreted as: (i) a strongly recommended for use in practice, (ii) recommended for use with some modification, or (iii) not recommended for use in practice. There was only one MS guideline in Indonesia, developed by Indonesian Neurological Association called “Perdossi” in 2015. Most of the domain score percentage were more than 50%. Domain 4 got the highest score percentage (94.44%), followed by domain 2 (88.89%), domain 1 (83.33%), and domain 5 (54.17%). The guideline had a spesific recommendations and easily identifiable in an algorithms, tables, or summary boxes. The guideline’s objectives, target populations, target users, and development group were clearly described. The lowest score percentage was domain 6 (33.33%) because lack of related informations. Critical appraisal of the Indonesian MS guideline using AGREE II instrument showed a good result. The Indonesian MS guideline was strongly recommended for use in practice.
Metrics
References
Mohamed K and Koriem M. (2016). Multiple sclerosis: new insights and trends. Asian Pacific Journal of Tropical Biomedicine, 6(5), 429–440.
Oreja-Guevara C, Wiendl H, Kieseier BC and Airas L. (2014). Specific aspects of modern life for people with multiple sclerosis: Considerations for the practitioner. Therapeutic Advances in Neurological Disorders, 7(2), 137–149.
Giampaolo DL, Bhigjee A, Retief C, Isaacs M, Britz M, Opperman D, Govender R and van Rensburg M. (2013). Guideline for the diagnosis and management of multiple sclerosis: A Southern African perspective. South African Medical Journal, 103(9 Suppl 3), 670-691.
Saguil A, Kane S and Farnell E. (2014). Multiple Sclerosis: A Primary Care Perspective. American Family Physician, 90(9), 644-65.
Minagar A. (2013). Current and Future Therapies for Multiple Sclerosis. Hindawi Publishing Corporation Scientifica.
Lassmann H, Brück W and Lucchinetti CF. (2007). The Immunopathology of Multiple Sclerosis: an Overview. Brain Pathology, 17:210–218.
Goldenberg MM. (2012). Multiple sclerosis review. Pharmacy and Therapeutics, 37(3), 175-184.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B and Wolinsky JS. (2011). Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. Annals of Neurology, 69, 292–302
Adams AL, Morgan MR and Lindsey WT. (2014). Multiple sclerosis: A review and treatment option updates. Alabama Pharmacy Association. DOI: 334.271.4222
Loma I and Heyman R. (2011). Multiple sclerosis: pathogenesis and treatment. Current Neuropharmacology. 9, 409-416.
Kes VB , Zavoreo I, Šerić V, Solter VV, Cesarik M, Hajnšek S, Pašić MB, Gabelić T, Bašić S, Butković SS, Lušić I, Grbelja LD, Vladić A, Bielen I, Antončić I and Demarin V. (2012). Recommendations for diagnosis and management of multiple sclerosis. Acta Clinica Croatica, 51(1).
Estiasari R, Machfoed MH, Purba J, Imran D, Sugianto P, Sudewi R, Komari N and Sucipto. (2015). Pedoman Diagnosis dan Tatalaksana Multipel Sklerosis di Indonesia. Perdossi: Jakarta.
Brouwers M, Kho ME, Browman GP, Cluzeau F, feder G, Fervers B, Hanna S and Makarski J. (2010). AGREE II: Advancing Guideline Development, Reporting and Evaluation in Healthcare. Canadian Medical Association Journal, 182, E839-42.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
